VITAMIN C MIX- acetaldehyde, cinnamic acid, gallicum acidum, hesperidin, malvin, quercetin, rutin, chlorophyll, aceticum acidum, Stati Uniti - inglese - NLM (National Library of Medicine)

vitamin c mix- acetaldehyde, cinnamic acid, gallicum acidum, hesperidin, malvin, quercetin, rutin, chlorophyll, aceticum acidum,

deseret biologicals, inc. - acetaldehyde (unii: go1n1zpr3b) (acetaldehyde - unii:go1n1zpr3b), cinnamic acid (unii: u14a832j8d) (cinnamic acid - unii:u14a832j8d), gallic acid monohydrate (unii: 48339473ot) (gallic acid - unii:632xd903sp), hesperadin (unii: ptr491os14) (hesperadin - unii:ptr491os14), malvin (unii: i9i120531l) (malvin - unii:i9i120531l), quercetin (unii: 9ikm0i5t1e) (quercetin - unii:9ikm0i5t1e), rutin (unii: 5g06tvy3r7) (rutin - unii:5g06tvy3r7), chlorophyll (unii: 00wnz48or9) (chlorophyll - unii:00wnz48or9), acetic aci - acetaldehyde 6 [hp_x] in 1 ml - temporary relief of symptoms related to vitamin c in foods and supplements including fatigue, upper respiratory, gastrointestinal, musculoskeletal and urinary symptoms. temporary relief of symptoms related to vitamin c in foods and supplements including fatigue, upper respiratory, gastrointestinal, musculoskeletal and urinary symptoms.

CHLOROGARD LIQ 50MG/15ML LIQUID Canada - inglese - Health Canada

chlorogard liq 50mg/15ml liquid

nature's way of canada ltd. - chlorophyllins - liquid - 50mg - chlorophyllins 50mg - mouthwashes and gargles

Avena Plus Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

avena plus

nature pack enterprise - chlorophyll; spirulina platensis.; semen plantago asiatica.; semen avena sativa; herba medicago sativa -

AFRICAN SEA COCONUT BRAND COUGH MIXTURE (AUSTRALIA) Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

african sea coconut brand cough mixture (australia)

luen fook medicine sdn. bhd - chlorophyll oil (ci 75810); tolu balsam; liquorice liquid extract bp; squill -

Avena Plus Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

avena plus

nature pack enterprise - chlorophyll; spirulina platensis.; semen plantago asiatica.; semen avena sativa; herba medicago sativa -

PERISYL perindopril erbumine 4 mg tablet blister pack Australia - inglese - Department of Health (Therapeutic Goods Administration)

perisyl perindopril erbumine 4 mg tablet blister pack

alphapharm pty ltd - perindopril erbumine, quantity: 4 mg - tablet - excipient ingredients: lactose; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; sodium bicarbonate; chlorophyllin-copper complex aluminium lake - perisyl is indicated for: ,1) the treatment of hypertension; ,2) the treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril has not been demonstrated for new york heart association category iv patients); and ,3) patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

PERISYL perindopril erbumine 8 mg tablet blister pack Australia - inglese - Department of Health (Therapeutic Goods Administration)

perisyl perindopril erbumine 8 mg tablet blister pack

alphapharm pty ltd - perindopril erbumine, quantity: 8 mg - tablet - excipient ingredients: lactose; microcrystalline cellulose; magnesium stearate; sodium bicarbonate; colloidal anhydrous silica; chlorophyllin-copper complex aluminium lake - perisyl is indicated for: ,1) the treatment of hypertension; ,2) the treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril has not been demonstrated for new york heart association category iv patients); and ,3) patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.